Aptose (APS) announces data from TUSCANY trial evaluating tuspetinib Jun 12, 2025 12:04PM
Aptose Biosciences (APTO) Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Feb 20, 2025 07:33AM
Aptose Biosciences (APTO) Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility Feb 13, 2025 04:30PM
Aptose Biosciences (APTO) Announces Positive Decision by Nasdaq Hearings Panel Dec 19, 2024 04:05PM
Aptose Biosciences (APTO) Announces Pricing of $8 Million Public Offering Nov 22, 2024 08:01AM